In reply [2]

JAMA

Volumn 295, Issue 20, 2006, Pages 2353-2354

  Mahaffey, Kenneth W ^a   Goodman, Shaun G ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; HEPARIN;

HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HYPERTENSION; LETTER; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; ST SEGMENT ELEVATION;

EID: 33646865950     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.295.20.2353-b     Document Type: Letter

References (2)

1. Anand SS, Yusuf S, Pogue J, Ginsberg JS, Hirsh J; Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. Circulation. 2003;107:2884-2888.
2. Petersen JL, Mahaffey KW, Becker RC, et al. A coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or heparin: design and rationale of the SYNERGY Library. Am Heart J. 2004;148:269-276.